Physician profile
Seth S Steinberg
NPI 1356381370
$4,081.21
in general payments reported to CMS, 2019-2025
27 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $259 · 2021: $387 · 2022: $484 · 2023: $449 · 2024: $781 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,761.57 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.30 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $318.96 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $190.13 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $148.43 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $143.09 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $126.95 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $125.63 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $102.18 | 2020-2024 | |
| Ironwood Pharmaceuticals, INC | $92.87 | 2019-2024 | |
| Redhill Biopharma INC. | $91.27 | 2020-2022 | |
| Celltrion USA INC. | $73.72 | 2024-2025 | Vegzelma |
| Intuitive Surgical, INC. | $56.61 | 2019 | |
| Intercept Pharmaceuticals, INC. | $56.02 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $50.09 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $49.54 | 2025 | Zenpep, Vowst |
| Lilly USA, LLC | $43.09 | 2025 | Omvoh |
| Pfizer INC. | $41.89 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $41.72 | 2019-2022 | |
| Braintree Laboratories, INC. | $39.08 | 2019-2020 | |
| Genzyme Corporation | $35.34 | 2025 | |
| Amgen INC. | $20.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.55 | 2024 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $15.02 | 2022 | |
| Ucb, INC. | $14.66 | 2019 | |
| Allergan, INC. | $13.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,608.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.